Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 2
2009 3
2010 2
2011 5
2012 4
2013 2
2014 4
2015 2
2016 2
2017 7
2018 6
2019 9
2020 11
2021 8
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

64 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacology of Medical Cannabis.
Amin MR, Ali DW. Amin MR, et al. Adv Exp Med Biol. 2019;1162:151-165. doi: 10.1007/978-3-030-21737-2_8. Adv Exp Med Biol. 2019. PMID: 31332738 Review.
The predominant psychotropic component is delta(9)-tetrahydrocannabinol (delta(9)-THC), while the major non-psychoactive ingredient is cannabidiol (CBD). These compounds have been shown to be partial agonists or antagonists at the prototypical cannabinoid receptors, CB1 an …
The predominant psychotropic component is delta(9)-tetrahydrocannabinol (delta(9)-THC), while the major non-psychoactive ingredient is ca
Biological bases for a possible effect of cannabidiol in Parkinson's disease.
Ferreira-Junior NC, Campos AC, Guimarães FS, Del-Bel E, Zimmermann PMDR, Brum Junior L, Hallak JE, Crippa JA, Zuardi AW. Ferreira-Junior NC, et al. Braz J Psychiatry. 2020 Apr;42(2):218-224. doi: 10.1590/1516-4446-2019-0460. Epub 2019 Jul 15. Braz J Psychiatry. 2020. PMID: 31314869 Free PMC article.
Cannabidiol (CBD), the major non-psychotomimetic constituent of cannabis, has received considerable research attention in the last decade. ...We searched MEDLINE (via PubMed) for indexed articles published in English from inception to 2019. The following keywords were used
Cannabidiol (CBD), the major non-psychotomimetic constituent of cannabis, has received considerable research attention in the last de
Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.
Cooray R, Gupta V, Suphioglu C. Cooray R, et al. Mol Neurobiol. 2020 Nov;57(11):4878-4890. doi: 10.1007/s12035-020-02054-6. Epub 2020 Aug 19. Mol Neurobiol. 2020. PMID: 32813239 Free PMC article. Review.
Neurodegeneration leading to Parkinson's disease (PD) and Alzheimer's disease (AD) has become a major health burden globally. ...Therefore, understanding the precise molecular cascade following cannabinoid treatment is suggested, focusing especially on gene expression to i
Neurodegeneration leading to Parkinson's disease (PD) and Alzheimer's disease (AD) has become a major health burden globally. ...Ther
Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis.
Philpott HT, O'Brien M, McDougall JJ. Philpott HT, et al. Pain. 2017 Dec;158(12):2442-2451. doi: 10.1097/j.pain.0000000000001052. Pain. 2017. PMID: 28885454 Free PMC article.
Osteoarthritis (OA) is a multifactorial joint disease, which includes joint degeneration, intermittent inflammation, and peripheral neuropathy. Cannabidiol (CBD) is a noneuphoria producing constituent of cannabis that has the potential to relieve pain. ...Prophylact …
Osteoarthritis (OA) is a multifactorial joint disease, which includes joint degeneration, intermittent inflammation, and peripheral n …
A systematic review of minor phytocannabinoids with promising neuroprotective potential.
Stone NL, Murphy AJ, England TJ, O'Sullivan SE. Stone NL, et al. Br J Pharmacol. 2020 Oct;177(19):4330-4352. doi: 10.1111/bph.15185. Epub 2020 Sep 1. Br J Pharmacol. 2020. PMID: 32608035 Free PMC article. Review.
Embase and PubMed were systematically searched for articles addressing the neuroprotective properties of phytocannabinoids, apart from cannabidiol and delta(9) -tetrahydrocannabinol, including delta(9) -tetrahydrocannabinolic acid, delta(9) -tetrahydrocannabivarin, cann
Embase and PubMed were systematically searched for articles addressing the neuroprotective properties of phytocannabinoids, apart from ca
Emerging potential of cannabidiol in reversing proteinopathies.
Dash R, Ali MC, Jahan I, Munni YA, Mitra S, Hannan MA, Timalsina B, Oktaviani DF, Choi HJ, Moon IS. Dash R, et al. Ageing Res Rev. 2021 Jan;65:101209. doi: 10.1016/j.arr.2020.101209. Epub 2020 Nov 9. Ageing Res Rev. 2021. PMID: 33181336 Review.
Along with oxidative stress and neuroinflammation, disruption in protein homeostasis (proteostasis), a network that constitutes protein surveillance system, plays a pivotal role in the pathobiology of these dementia disorders. Cannabidiol (CBD), a non-psychotropic phytocan …
Along with oxidative stress and neuroinflammation, disruption in protein homeostasis (proteostasis), a network that constitutes protein surv …
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Abílio VC. Peres FF, et al. Front Pharmacol. 2018 May 11;9:482. doi: 10.3389/fphar.2018.00482. eCollection 2018. Front Pharmacol. 2018. PMID: 29867488 Free PMC article. Review.
Cannabidiol is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. ...Here, we review these clinical and pre-clinical studies and draw attention to the potential of cannabidiol
Cannabidiol is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and ne
The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.
Karl T, Garner B, Cheng D. Karl T, et al. Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):142-160. doi: 10.1097/FBP.0000000000000247. Behav Pharmacol. 2017. PMID: 27471947 Review.
The brains of AD patients are characterized by the deposition of amyloid-beta and hyperphosphorylated forms of tau protein. AD brains also show neurodegeneration and high levels of oxidative stress and inflammation. The phytocannabinoid cannabidiol (CBD) possesses n …
The brains of AD patients are characterized by the deposition of amyloid-beta and hyperphosphorylated forms of tau protein. AD brains also s …
Cannabidiol anticonvulsant effect is mediated by the PI3Kγ pathway.
Lima IVA, Bellozi PMQ, Batista EM, Vilela LR, Brandão IL, Ribeiro FM, Moraes MFD, Moreira FA, de Oliveira ACP. Lima IVA, et al. Neuropharmacology. 2020 Oct 1;176:108156. doi: 10.1016/j.neuropharm.2020.108156. Epub 2020 Jun 20. Neuropharmacology. 2020. PMID: 32574650
This work aims to investigate if the anticonvulsant and neuroprotective effects of cannabidiol (CBD) are mediated by PI3Kgamma. In vitro and in vivo experiments were performed on C57Bl/6 wild-type (WT) and PI3Kgamma(-)(/-) mice. ...CDB increased latency and reduced the sev …
This work aims to investigate if the anticonvulsant and neuroprotective effects of cannabidiol (CBD) are mediated by PI3Kgamma. In vi …
Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid.
Kozela E, Juknat A, Vogel Z. Kozela E, et al. Int J Mol Sci. 2017 Jul 31;18(8):1669. doi: 10.3390/ijms18081669. Int J Mol Sci. 2017. PMID: 28788104 Free PMC article. Review.
The cannabinoid system and its ligands have been shown to interact and affect activities of astrocytes. Cannabidiol (CBD) is the main non-psychotomimetic cannabinoid derived from Cannabis. ...The collected data shows that increased astrocyte activity is suppressed in the p …
The cannabinoid system and its ligands have been shown to interact and affect activities of astrocytes. Cannabidiol (CBD) is the main …
64 results